Cargando…

Validation of the ELAN-HF Score and self-care behaviour on the nurse-led heart failure clinic after admission for heart failure

AIM: To validate the predictive value of the European coLlaboration on Acute decompeNsated Heart Failure (ELAN-HF) score, and to assess the effect of self-care behaviour on readmission and mortality in patients after admission with acute decompensated heart failure (ADHF). DESIGN: Quantitative, pros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vinck, T. A. M., Deneer, R., Verstappen, CCAG, Kok, WE, Salah, K., Scharnhorst, V., Otterspoor, LC
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210612/ https://www.ncbi.nlm.nih.gov/pubmed/35729554 http://dx.doi.org/10.1186/s12912-022-00914-1

Ejemplares similares

External Validation of the ELAN‐HF Score, Predicting 6‐Month All‐Cause Mortality in Patients Hospitalized for Acute Decompensated Heart Failure
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF)
por: Patil, Tanvi, et al.
Publicado: (2022)

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

The Role of Ambulatory Heart Failure Clinics to Avoid Heart Failure Admissions
por: He, Jessica, et al.
Publicado: (2019)

The Canadian Heart Failure (CAN-HF) Registry: A Canadian Multicentre, Retrospective Study of Inpatients With Heart Failure
por: Poon, Stephanie, et al.
Publicado: (2022)

Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study
por: Wang, Michael C., et al.
Publicado: (2021)

Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Admission hyponatraemia as heart failure events predictor in patients with acute heart failure
por: Sarastri, Yuke, et al.
Publicado: (2023)

Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
por: Correia, Luis Cláudio Lemos, et al.
Publicado: (2016)

The Heart Failure Optimization Study (HF-OPT): rationale and design
por: Sanchez, R., et al.
Publicado: (2023)

Effects of the Cardiac and Comorbid Conditions Heart Failure (3C-HF) Score at Admission on Life Space at Three Months after Hospital Discharge in Elderly Patients with Heart Failure: A Short Report
por: Naito, Koichi, et al.
Publicado: (2020)

Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry
por: Linssen, G. C. M., et al.
Publicado: (2020)

Corrigendum: Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study
por: Wang, Michael C., et al.
Publicado: (2022)

The effect of nurse-led interventions on re-admission and mortality for congestive heart failure: A meta-analysis
por: Qiu, Xiaoqin, et al.
Publicado: (2021)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study
por: Domingo, Mar, et al.
Publicado: (2021)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Heart Failure after Laboratory Confirmed Influenza Infection (FLU-HF)
por: Sin, Phyllis, et al.
Publicado: (2022)

The COVID-19 pandemic and heart failure: lessons from GUIDE-HF( )
por: Cowie, Martin R, et al.
Publicado: (2022)

Perils and Pitfalls With Associations in Heart Failure, Particularly in HF-pEF
por: Carson, Peter E.
Publicado: (2023)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Heart transplantation for end-stage heart failure combined with Q fever isolated to the heart: a case report
por: van ‘t Veer, Marcel, et al.
Publicado: (2020)

Clinical presentation at first heart failure hospitalization does not predict recurrent heart failure admission
por: Kosztin, Annamaria, et al.
Publicado: (2017)

Emergency Heart failure Mortality Risk Grade may help to reduce heart failure admissions
por: van Hattem, N. E., et al.
Publicado: (2022)

Effects of COVID-19 on heart failure admissions
por: Chouairi, Fouad, et al.
Publicado: (2023)

Decrease in the 30-day heart failure (HF) Rehospitalization Rate after the implementation of a HF managed protocol
por: Correa, AG, et al.
Publicado: (2009)

Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)
por: von Haehling, Stephan, et al.
Publicado: (2010)

Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
por: Lupón, Josep, et al.
Publicado: (2014)

Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF)
por: Ezekowitz, Justin A, et al.
Publicado: (2016)

Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF)
por: Rahimi, Farzad, et al.
Publicado: (2021)

The Caregiver Burden Questionnaire for Heart Failure (CBQ-HF): face and content validity
por: Humphrey, Louise, et al.
Publicado: (2013)

The need to apply the best therapy in heart failure – the era after PARADIGM-HF
por: Lelonek, Malgorzata
Publicado: (2016)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

An aetiology‐based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH‐HF) trial
por: Szalewska, Dominika, et al.
Publicado: (2021)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Publisher Erratum: The Heart Failure Optimization Study (HF‑OPT): rationale and design
por: Sanchez, R., et al.
Publicado: (2023)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9jql0sbl3ldf0giv16i6upeo0q